
- /
- Supported exchanges
- / US
- / ONC.NASDAQ
BeiGene, Ltd. (ONC NASDAQ) stock market data APIs
BeiGene, Ltd. Financial Data Overview
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; Ociperlimab (BGB-A1217), a TIGIT inhibitor; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get BeiGene, Ltd. data using free add-ons & libraries
Get BeiGene, Ltd. Fundamental Data
BeiGene, Ltd. Fundamental data includes:
- Net Revenue: 3 810 M
- EBITDA: -401 976 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-27
- EPS/Forecast: -1.0175
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BeiGene, Ltd. News

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against the ...


US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results
It's been a good week for BeiGene, Ltd. (NASDAQ:ONC) shareholders, because the company has just released its latest yearly results, and the shares gained 6.4% to US$272. Revenues were a bright spot, w...

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?
We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against other best immunology stocks to bu...

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
BeiGene (NASDAQ:ONC) Full Year 2024 Results Key Financial Results Revenue: US$3.81b (up 55% from FY 2023). Net loss: US$644.8m (loss narrowed by 27% from FY 2023). US$6.12 loss per share (improved f...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.